All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
HONG KONG – Singaporean biotech company Aum Biosciences Pte. Ltd. has in-licensed a potentially first-in-class PIM/PI3K/mTOR inhibitor from Inflection Biosciences Ltd., of Dublin and London, to develop it globally to treat a wide range of cancers.